JP2006340672A - Food having effect of reducing perimeter diameter of waist and perimeter diameter of hip - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a food having the effects of reducing the perimeter diameter of a waist and perimeter diameter of a hip. <P>SOLUTION: This food having the effects of reducing the perimeter diameter of the waist and perimeter diameter of the hip contains lysine, proline, alanine, arginine and a conjugated linoleic acid as active ingredients. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a food having an effect of reducing a waist circumference and a hip circumference.

  Obesity is not simply a large body weight but a condition in which adipose tissue is excessively accumulated. Obesity is type 2 diabetes, impaired glucose tolerance, abnormal lipid metabolism, hypertension, hyperuricemia, gout, sleep It is referred to as a disease unit called “obesity” especially when it causes a health disorder such as apnea syndrome, fatty liver, osteoarthritis, lumbar spondylosis, menstrual abnormality, or when it is likely to be caused in the future. In addition, even if individual test data such as cholesterol level, blood pressure, blood sugar, etc. are at the level of caution, if they are duplicated, it is found that arteriosclerosis is promoted and fatal myocardial infarction and cerebral infarction are likely to occur. I came. Underlying these diseases are various metabolic abnormalities such as sugar metabolism and lipid metabolism, and the pathological conditions that overlap with such risks of anti-glycemia, hypertension, and high cholesterol have recently been described as “Metabolic Syndrome”. ) ”.

  According to the recently published diagnostic criteria for metabolic syndrome, the waist circumference is first measured, and there is a waist circumference of 85 cm or more for men and 90 cm or more for women, and then hypertriglycerideemia of 150 mg / dL or more, 40 mg 2 of 3 risks of either or both of low HDL cholesterolemia </ dL, systolic blood pressure> 130 mmHg, diastolic blood pressure> 85 mmHg, or fasting blood glucose> 110 mg / dL If you have more than one risk, you are diagnosed with metabolic syndrome. Currently, it is estimated that there are more than 10 million patients in the country that meet this diagnostic criterion.

In particular, compared to “pear-type obesity” where subcutaneous fat is attached to the buttocks and lower abdomen, in the case of “apple-type obesity” where fat accumulates around the internal organs, it is more likely to suffer from metabolic syndrome Is done. If the circumference of the waist is 85 cm or more for men and 90 cm or more for women, the visceral fat area for both men and women exceeds 100 cm ^2, which is a standard for dangerous water areas, and it is important to reduce the waist circumference first.
International publication number: WO 00/64854 Patent No. 3487079 Explanation of fat burning amino acids: http://purelife.jp/amino/aruaru/sibou.html

  An object of the present invention is to provide a food that exhibits the effect of reducing the waist circumference and the hip circumference more effectively by combining with exercise.

  The present inventors ingest a combination of five types of food ingredients, particularly lysine, alanine, proline, arginine and conjugated linoleic acid, among many food materials that have been reported to have anti-obesity effects during aerobic exercise. As a result, it has been found that the waist can be effectively reduced, and the present invention has been completed.

The present invention provides foods having the effect of reducing the waist circumference and / or hip circumference shown in the following (1) to (4).
(1) A food having an effect of reducing waist circumference and / or hip circumference, containing lysine, proline, alanine, arginine and conjugated linoleic acid as active ingredients.
(2) 48 to 58 parts by weight of lysine, 37 to 47 parts by weight of proline, 27 to 37 parts by weight of alanine, 58 to 68 parts by weight of arginine, and 150 to 250 parts by weight of conjugated linoleic acid The food having the effect of reducing the waist circumference and / or hip circumference of (1) above.
(3) 4 hard capsule foods containing 48-58 mg lysine, 37-47 mg proline, 27-37 mg alanine, 58-68 mg arginine per tablet, and 4 soft capsule foods containing 150-200 mg conjugated linoleic acid per tablet A food having a waist circumference diameter and / or hip circumference diameter reduction effect.
(4) 4 hard capsule foods containing 52.9 mg lysine, 41.8 mg proline, 32.3 mg alanine, 63.0 mg arginine per tablet, and 4 soft capsule foods containing 200 mg conjugated linoleic acid per tablet A food having a waist circumference and / or hip circumference reduction effect.

  According to the present invention, by taking a food containing an effective amount of lysine, proline, alanine, arginine and conjugated linoleic acid, it is possible to contribute to reduction of waist circumference and / or hip circumference and prevention of metabolic syndrome. .

  The food having an effect of reducing the waist circumference and / or hip circumference of the present invention comprises lysine, proline, alanine, arginine and conjugated linoleic acid, which are essential five components, 48 to 58 parts by weight of lysine and 37 to 47 proline. It contains 27 to 37 parts by weight of alanine, 58 to 68 parts by weight of arginine, and 150 to 250 parts by weight of conjugated linoleic acid.

  Lysine, proline, alanine, and arginine used in the present invention are amino acids that are widely present in nature as food components in foods. It is not widely used as a highly safe food additive. Lysine, proline, alanine and arginine are industrially produced and commercially available. Examples include L-lysine, L-proline, L-alanine and L-arginine manufactured by Ajinomoto Co., Inc.

Conjugated linoleic acid used in the present invention is a fatty acid present in the form of glycerides in plants, and is also converted and produced from linoleic acid by the action of some microorganisms in the digestive tract of animals and absorbed into the body. Are known. Conjugated linoleic acid is also produced industrially and is commercially available. Examples of the conjugated linoleic acid products include conjugated linoleic acid-containing fatty acids (product name: active linole, English name: CLA 80HG) manufactured by Kenko Tsusho, CLA80 active linole manufactured by Linol Oil & Fats, Tonaline manufactured by Maypro, and the like. These are produced by conjugating natural cis-type linoleic acid (C18: 2) under alkali, and the main components are cis-9, trans-11 or trans-9,
It is a free fatty acid of cis-11, trans-10, cis-12 and contains several other positions or geometric isomers.

  As lysine, proline, alanine, arginine, and conjugated linoleic acid used in the present invention, 100% pure products may be used, or materials containing them may be used. In addition, since lysine, proline, alanine and arginine are generally supplied in raw materials in powder form, and conjugated linoleic acid is supplied in liquid form, only four components of lysine, proline, alanine and arginine are separately provided. It is also possible to produce hard capsules and tablets in a quantity, and separately produce only conjugated linoleic acid, in a soft capsule form, and each hard capsule and soft capsule obtained can be packaged and provided in the above-mentioned blended parts by weight. is there. Each manufacturing method is well known in the art.

  In addition, after suspending and dispersing lysine, proline, alanine and arginine in a suitable base such as olive oil, it is mixed with conjugated linoleic acid and contains the five essential components of lysine, proline, alanine, arginine and conjugated linoleic acid. Soft capsules are also possible.

  In addition, in the production of the food of the present invention, the above five essential components may be contained, or various flavors, fruit juice powder, sweeteners such as sugar and fructose, and sourness such as citric acid and malic acid as necessary. It is also possible to add subcomponents such as additives, stabilizers, thickeners, grain flours, vitamins, minerals and the like.

  Lysine, proline, alanine, arginine and conjugated linoleic acid can be used as food and drink together with orally administrable substances. For example, various flavors, fruit juice powder, sweeteners such as sugar and fructose, acidulants such as citric acid and malic acid, stabilizers, thickeners, cereal flour, vitamins, minerals, etc. It can be used in the form of noodles, baked confectionery, cream, rice cake, chewing gum, tablet confectionery, tea, coffee, fruit juice beverage, fermented milk, carbonated beverage, pudding, jelly and the like. Similarly, it can be processed into a tablet, capsule (hard capsule, soft capsule), granule, salad oily food or the like and used in the form of a dietary supplement.

  In the production or ingestion of the food of the present invention, when a lipid other than conjugated linoleic acid is used in combination, it is desirable to use an oil or fat material having a low linoleic acid content. Specifically, it is preferable to use fats and oils such as butter oil, fish oil, perilla oil, sesame oil, palm oil, coconut oil, linseed oil, olive oil, beef tallow and lard. This is because when a fat containing a large amount of linoleic acid is used in combination, the physiological effect of conjugated linoleic acid may be inhibited.

  In order to obtain a more effective waist circumference and hip circumference reduction effect, the food of the present invention is used 10 to 50 minutes before aerobic exercise, preferably 20 to 40 minutes before, and / or immediately after aerobic exercise to 30. Ingested after a minute, preferably immediately after 10 minutes after aerobic exercise.

  Hereinafter, examples will be given to describe the present invention in more detail, but the present invention is not limited thereto.

In order to demonstrate the effect of the food of the present invention, the present inventor conducted the following clinical test.
[Outline of clinical trial]
(1) Study design The study design was a double-blind, parallel group study.
(2) Target person
Healthy overweight individuals with a BMI of 23 or more and less than 30.
(3) Food used
Test food / fat burning amino acid hard capsule: 12.9 mg lysine, 41.8 mg proline, alanine
Hard capsule food containing 32.3mg and arginine 63.0mg.
Conjugated linoleic acid soft capsule: A soft capsule food containing 200 mg of conjugated linoleic acid per grain.
Pseudo-control food / fat-burning amino acid hard capsule pseudo-control food: Hard capsule food containing corn starch instead of fat-burning amino acid.
・ Pseudo control food of conjugated linoleic acid soft capsule: Soft capsule food containing soybean oil instead of conjugated linoleic acid.

(4) Exercise Exercise was performed in the order of stretching first, then strength training, then whole body exercise (aerobic exercise) and finally stretching again. Specific contents are shown below.

(5) Administration method and dosage Each of the assigned foods was ingested with water at the following dosage twice a day, 30 minutes before aerobic exercise and immediately after exercise.

(6) Study period and schedule The pre-observation period was 2 weeks, the observation period (administration period) was 12 weeks, and the post-observation period was 4 weeks.

(7) Implementation procedure The following observations and inspections were conducted at each time point. In addition, when it was judged that it was necessary other than that, observations and inspections were conducted as needed.
Pre-observation period Acquisition of consent, subject background, examination (subjective symptoms / objective findings), confirmation of selection criteria / exclusion criteria, measurement of body weight / body fat ratio / W / H ratio, clinical examination.
Observation period (12 weeks, every 2 weeks)
Examination (adverse events), confirmation of selection criteria / exclusion criteria, measurement of body weight, body fat percentage, W / H ratio, clinical examination (three times during the observation period).
Post-observation period: Examination (adverse events), confirmation of selection criteria / exclusion criteria, measurement of body weight, body fat percentage, W / H ratio, clinical examination.

(8) Observation / inspection items
Subject background The following items were investigated during the pre-observation period and completed in the subject report.
Subject identification code, gender (for women, pregnancy status), date of birth, written consent date, height, diagnosis name, presence or absence of allergies, current medical history and contents, past history that may conflict with exclusion criteria Presence / absence, content and time of onset, presence / absence of administration of study drug within 3 months before obtaining consent, body weight / body fat percentage / W / H ratio.
The onset or worsening of subjective symptoms, objective findings, etc. The study investigator, etc. should indicate the symptoms, onset date, disappearance date when the subject's subjective symptoms / subjective symptoms have developed or worsened after the start of the study. The patient was examined and listened to and recorded, and the contents were entered in the subject report.
Body weight, body fat percentage, W / H ratio Body weight and body fat percentage were measured with the same scale and body fat scale at each visit. Since body fat is easily affected by the amount of moisture in the body and the dryness of the measurement site, it was performed at the same conditions and at the same time throughout the test period.
Clinical examination items The following items were examined during the observation period and at the end (at the end of administration but at the time of discontinuation). For hematological tests, blood biochemical tests, and urinalysis results, the test values are judged to be normal or abnormal from the reference values. If the observation period is normal and abnormal at the end, and both at the observation period and at the end When abnormal and showed a tendency to deteriorate at the end, the fluctuation was judged as “present” and the reason for the fluctuation was described. If the doctor judged that the change was abnormal from a clinical point of view, a follow-up study was conducted until it returned to the previous value in principle.
(Hematology test)
Red blood cell count, hemoglobin, hematocrit value, white blood cell count, white blood cell fraction, platelet count (blood biochemical examination)
Total protein, albumin, total cholesterol, HDL cholesterol, free fatty acid, neutral fat, urea nitrogen, uric acid, creatinine, AST (GOT), ALT (GPT), γ-GTP, blood glucose, insulin (urinalysis)
Urine protein, urine sugar, urine sediment (red blood cells, white blood cells, cast)
Meal survey <br/> The subject himself / herself recorded in a meal survey slip.
Test food intake survey and exercise survey The subjects themselves recorded in a diary. Daily exercise status was recorded using Lifecorder EX (manufactured by Zuzuken Co., Ltd.).

(10) Statistical analysis The amount of change from before the start of administration to 12 weeks after administration of the main endpoint was compared using a 2-sample t-test within each group of the test food group and the control food group. For reference, the values at each time point during the administration period of the main endpoint were compared with the values before the start of administration using a 1-sample t-test. The values of other items (clinical tests) at each time point during the administration period were compared with those before the start of administration using a 1-sample t-test. Multiplicity was not considered, and the superiority level was 5 on both sides.

[Clinical trial results]
<1> Waist circumference (Fig. 1)
There was a significant decrease compared to the LS group after 2, 6, 12, and 16 weeks in the LAAA4CLA4 group (p <0.05).
<2> Hip circumference (Fig. 2)
There was a significant decrease compared to the LS group after 6, 8, 12, and 16 weeks in the LAAA4CLA4 group (p <0.05).
<3> Secondary evaluation items
Body weight An increase due to seasonal variation (autumn to winter) was expected, but after 8 weeks in the LPAA4 CLA4 group, the increase was significantly suppressed compared to the LS group (p <0.05).
There was no difference between the total cholesterol groups.
There was no difference between the triglyceride groups.
Safety assessment
AST (GOT) was significantly higher than before ingestion at 8, 12, and 16 weeks in LPAA4CLA4 group, and ALT (GPT) was significantly lower than before ingestion after 16 weeks in LPAA4 group. It was not a change that caused problems. There was no significant change in γ-GTP before and after ingestion. For albumin, total protein, creatinine, and urea nitrogen, there were groups and time points where significant fluctuations were observed before and after ingestion, but all were within a clinically acceptable range. For HDL-cholesterol, uric acid, and glucose, there were groups and time points where significant fluctuations were observed before and after ingestion, but all were within a clinically acceptable range. There was no significant change in insulin before and after ingestion. In addition, blood pressure and hematological examination items were examined, but there were no clinically relevant changes.

  ADVANTAGE OF THE INVENTION By this invention, the foodstuff which has the waist circumference diameter and / or hip circumference diameter reduction effect which contributes to prevention of the prevalent metabolic syndrome is provided.

It is the figure which showed the change of the waist periphery diameter of each group. It is the figure which showed the change of the hip periphery diameter of each group.

Claims (4)

  A food having an effect of reducing waist circumference and / or hip circumference, comprising lysine, proline, alanine, arginine and conjugated linoleic acid as active ingredients.   48 to 58 parts by weight of lysine, 37 to 47 parts by weight of proline, 27 to 37 parts by weight of alanine, 58 to 68 parts by weight of arginine, and 150 to 250 parts by weight of conjugated linoleic acid. 1. A food having an effect of reducing the waist circumference and / or hip circumference according to 1.   4 hard capsule foods containing 48-58 mg lysine, 37-47 mg proline, 27-37 mg alanine, 58-68 mg arginine per tablet, and 4 soft capsule foods containing 150-200 mg conjugated linoleic acid per tablet A food having a characteristic effect of reducing the waist circumference and / or hip circumference.   Waist circumference characterized by containing 4 hard capsule foods containing 52.9 mg lysine, 41.8 mg proline, 32.3 mg alanine, 63.0 mg arginine per tablet, and 4 soft capsule foods containing 200 mg conjugated linoleic acid per tablet And / or food having an effect of reducing the hip circumference.